Rock Springs Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-3,685,000
| Closed | -$22.2M | – | 141 |
|
|
2019
Q4 | $22.2M | Sell |
3,685,000
-140,000
| -4% | -$810K | 0.7% | 56 |
|
|
2019
Q3 | $13.8M | Buy |
3,825,000
+875,000
| +30% | +$3.37M | 0.55% | 60 |
|
|
2019
Q2 | $7.91M | Buy |
2,950,000
+250,000
| +9% | +$738K | 0.29% | 88 |
|
|
2019
Q1 | $7.99M | Buy |
2,700,000
+375,000
| +16% | +$921K | 0.31% | 91 |
|
|
2018
Q4 | $3.7M | Sell |
2,325,000
-75,000
| -3% | -$212K | 0.17% | 109 |
|
|
2018
Q3 | $8.83M | Buy |
2,400,000
+50,000
| +2% | +$149K | 0.32% | 90 |
|
|
2018
Q2 | $6.65M | Buy |
2,350,000
+100,000
| +4% | +$341K | 0.26% | 108 |
|
|
2018
Q1 | $8.35M | Hold |
2,250,000
| – | – | 0.36% | 90 |
|
|
2017
Q4 | $6.48M | Buy |
2,250,000
+118,600
| +6% | +$431K | 0.29% | 95 |
|
|
2017
Q3 | $9.57M | Buy |
2,131,400
+406,400
| +24% | +$1.8M | 0.44% | 74 |
|
|
2017
Q2 | $7.92M | Buy |
1,725,000
+225,000
| +15% | +$904K | 0.4% | 74 |
|
|
2017
Q1 | $6.32M | Buy |
1,500,000
+125,000
| +9% | +$519K | 0.36% | 78 |
|
|
2016
Q4 | $5.68M | Buy |
1,375,000
+59,000
| +4% | +$314K | 0.38% | 73 |
|
|
2016
Q3 | $10.7M | Buy |
1,316,000
+3,500
| +0.3% | +$29.8K | 0.67% | 50 |
|
|
2016
Q2 | $10.2M | Buy |
1,312,500
+92,500
| +8% | +$794K | 0.76% | 44 |
|
|
2016
Q1 | $9.42M | Buy |
1,220,000
+115,000
| +10% | +$842K | 0.79% | 41 |
|
|
2015
Q4 | $11.9M | Sell |
1,105,000
-20,000
| -2% | -$182K | 0.9% | 36 |
|
|
2015
Q3 | $7.77M | Buy |
1,125,000
+25,000
| +2% | +$204K | 0.63% | 57 |
|
|
2015
Q2 | $9.75M | Buy |
1,100,000
+500,000
| +83% | +$4.73M | 0.71% | 46 |
|
|
2015
Q1 | $5.92M | Buy |
600,000
+235,000
| +64% | +$2.93M | 0.55% | 64 |
|
|
2014
Q4 | $4.47M | Buy |
+365,000
| New | +$4.46M | 0.52% | 57 |
|
Rock Springs Capital Management's ACHN Position: Q1 2020 in Review
Rock Springs Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 3,685,000 shares — an estimated $22.2M sold.
Rock Springs Capital Management first reported a position in ACHN in Q4 2014 and held it in 21 quarters. The position peaked at $22.2M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Rock Springs Capital Management reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Rock Springs Capital Management sold 3,685,000 Achillion Pharmaceuticals shares in Q1 2020, an estimated $22.2M.
- Rock Springs Capital Management first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 21 quarters.
- Rock Springs Capital Management's Achillion Pharmaceuticals position peaked at $22.2M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Rock Springs Capital Management's 13F filing for Q1 2020, filed 15 May 2020.